Tag: Onxeo
Onxeo changes its name and becomes Valerio Therapeutics following the approval of the Annual General Meeting of June 6, 2023 – 06/06/2023 at 6:30 p.m.
All the resolutions approved by the Board of Directors were adopted Shefali Agarwal, Chairman and Chief Executive Officer, declares: “I would like to thank all of our shareholders for their…
Onxeo will publish its annual results on April 21, 2023 – 04/14/2023 at 17:35
Paris (France), April 14, 2023 – 5:35 p.m. CEST – Onxeo SA (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA…
Onxeo postpones the presentation of its annual results from April 14 to 21, 2023 – 04/14/2023 at 18:08
(AOF) – Initially scheduled for April 14, Onxeo today announced a new date for the publication of its 2022 annual results. The biotechnology company will present its results on April…
Onxeo: modification of publication dates
AS Published on 03/14/2023 at 8:56 p.m. Photo credit © ONXEO (Boursier.com) — Onxeo SA…
Onxeo: report of the EGM of February 6, 2023 – 02/06/2023 at 7:30 p.m.
Paris (France), February 6, 2023 – 7:30 p.m. CET – Onxeo SA (Euronext Growth Paris: ALONX), hereinafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of…
Onxeo: program to follow
CL Published on 01/27/2023 at 6:01 p.m. Photo credit © *ONXEO …
Onxeo announces its 2023 financial calendar – 2023-01-27 18:00
Paris (France), January 27, 2023 – 6 p.m. CET – Onxeo SA (Euronext Growth Paris: ALONX), hereinafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of…
Onxeo: “encouraging” preliminary data for the anti-cancer drug AsiDNA – 01/25/2023 at 18:26
(AOF) – Onxeo provides an update on the clinical development program for its first-in-class drug candidate AsiDNA: the company reports encouraging preliminary data demonstrated by the interim analysis. This multicenter…
Onxeo: a second drug candidate for the treatment of solid tumors
By Olivier Cheilan Published on 11/30/2022 at 6:22 p.m. Photo credit © *ONXEO …
Onxeo publishes its financial results for H1 2022 and provides an update on its activities – 09/13/2022 at 19:45
Refocusing of R&D efforts and acceleration of preclinical and clinical programs internationallyCash of €26.9 million as of June 30, 2022Financial visibility assured until the 2nd quarter of 2023 Dr. Shefali…
Onxeo: First patient for a phase 1b/2 trial
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Onxeo: inclusion of the 1st patient in the phase 1b/2 clinical trial in recurrent high-grade glioma in children – 09/01/2022 at 20:15
Recurrent high-grade glioma in children: Onxeo announces the inclusion of the 1st patient in the phase 1b/2 clinical trial conducted by the European consortium ITCC, with the support of Institut…